A new book exploring the journey of gene therapy research for inherited retinal diseases is bringing renewed attention to the promise of precision medicine in ophthalmology. Our Hope for Gene Therapy, written by ophthalmologist and researcher Ian M. MacDonald, member of the Retina4Future COST Action, traces decades of scientific advances in the understanding of choroideremia, a rare inherited disorder that causes progressive vision loss.
The book recounts the development of pioneering research that led to the first experimental gene therapy trial for choroideremia in Canada in 2015, highlighting both the scientific challenges and the human stories behind the search for treatment.
By combining personal experiences with the history of retinal genetics and translational medicine, the publication offers readers an accessible perspective on how gene therapy is transforming the future of inherited retinal diseases and providing new hope for patients and families worldwide.
More information about the book is available at Our Hope for Gene Therapy.
